hidden overlay
Class action banner image

MiMedx Securities Fraud Lawsuit

MiMedx Securities Fraud Lawsuit

Morgan & Morgan’s securities attorneys are investigating claims of possible securities fraud involving MiMedx Group, Inc. (ticker symbol: MDXG). The Food and Drug Administration (“FDA”) has accused the Georgia-based company of producing certain pharmaceutical products without first obtaining necessary licenses and approval from the FDA.

The securities attorneys at Morgan & Morgan would like to hear from you if you are a MiMedx shareholder who has experienced a financial loss due to the large drop in the company’s share price following the announcement of the alleged FDA violations. To learn more about how you may be able to recover compensation through a class action lawsuit, please fill out our free, no-obligation case review form today.

MiMedx Shares Plummet Following FDA Notice Alleging Company Sold Pharmaceutical Products Without Obtaining Necessary Licenses

In a letter dated August 28, 2013, the FDA asserted that MiMedx violated the Food, Drug, and Cosmetic Act and the Public Health Service Act by failing to obtain proper licenses needed to sell certain products used to reduce inflammation and scar tissue formation, as well as enhance wound healing of soft tissues. Such FDA licenses are only issued after a showing of safety and efficacy for the product’s intended use.

On September 4, 2013, news of these alleged FDA violations became public, causing shares of MiMedx to lose 36.5 percent of their value. MiMedx shares ended the trading day down $2.21 per share and financial analysts estimate that the company’s shareholders lost approximately $213 million in market value.

The securities attorneys at Morgan & Morgan are investigating whether MiMedx executives had prior knowledge that the company may have needed licenses from the FDA to sell its products. In addition, our attorneys are reviewing whether MiMedx had proper policies and procedures in place to ensure that the company was in compliance with the FDA’s licensing requirements.

Who Can Recover Damages Through a Securities Fraud Class Action Lawsuit?

You may be able to participate in the MiMedx shareholder litigation if you purchased shares of MiMedx common stock between October 30, 2012 and September 4, 2013. (Please note that this prospective class period may change as the litigation progresses.)

In addition, if you are a current or former MiMedx employee who owns MiMedx stock through a company-sponsored 401(k) plan or employee stock purchase plan, you may be able to participate in a securities fraud or breach of fiduciary duty lawsuit filed under the Employee Retirement Income Security Act (“ERISA”).

Furthermore, other investors, such as swing traders and purchasers of options positions in MiMedx who suffered losses, may also be able to participate in this class action litigation.

If you are an investor in MiMedx common stock or options contracts involving MiMedx, please complete our free case review form to learn more about how our class action lawyers may be able to help you recover compensation through a potential securities fraud lawsuit.

Contact Our MiMedx Securities Fraud Lawsuit Office

Share your experience and we will call you

Free Case Evaluation

Tell us about your situation so we can get started fighting for you. We tailor each case to meet our clients' needs.